Luduxin

Luduxin is a proprietary nutraceutical formulation developed by Metagenics, Inc., consisting of rho iso-alpha acids (RIAA) derived from hops (*Humulus lupulus*). It is classified as a selective kinase response modifier (SKRM), a term used to describe compounds that modulate signal transduction pathways associated with inflammation by influencing kinase activity. Unlike traditional non-steroidal anti-inflammatory drugs (NSAIDs) that directly inhibit cyclooxygenase (COX) enzymes, Luduxin is designed to support joint health by modifying the cellular response to inflammatory stimuli. It is marketed as a medical food or nutraceutical, primarily distributed through healthcare practitioners, and is protected under U.S. patent 7,270,835.

Brand names

Luduxin

Other names

rho iso-alpha acidsRIAA